Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:IRWD  
10.18
-0.26 (-2.44%)
Products, Regulatory

Ironwood Pharmaceuticals Reports Positive Topline Data From Phase Iii Trial Of Linzess® (Linaclotide) In Pediatric Patients Aged 6-17 With Functional Constipation

Published: 09/06/2022 11:58 GMT
Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A (IRWD) - Ironwood Pharmaceuticals Reports Positive Topline Data From Phase Iii Trial of Linzess® (linaclotide) in Pediatric Patients Aged 6-17 With Functional Constipation.
Ironwood Pharmaceuticals Inc - Study Met Primary and Secondary Endpoints -- Results Add to Body of Data Supporting Safety of Linaclotide.
Ironwood Pharmaceuticals Inc - Ironwood and Its Partner, Abbvie, to Evaluate a Potential Supplemental New Drug Application (snda) Submission.